On November 7, 2024, Assembly Biosciences, Inc., a biotechnology company, announced its financial results for the third quarter ending September 30, 2024. The company reported a cash position of $95.0 million, which is projected to fund operations into the first quarter of 2026. Revenue from collaborative research was $6.8 million, attributed to the collaboration with Gilead Sciences, Inc. Research and development expenses increased to $13.5 million due to more candidates in development, while general and administrative expenses remained stable at $4.3 million. The net loss for the quarter was $9.6 million, or $1.51 per share, an improvement from the $14.4 million loss in the same period of 2023. Assembly Biosciences also highlighted progress in its clinical pipeline, including positive Phase 1a interim data for ABI-5366, a candidate for recurrent genital herpes, and the initiation of Phase 1b trials. The company expects to release interim data for two other candidates, ABI-4334 and ABI-5366, by the end of 2024 and the first half of 2025, respectively. Additionally, two more candidates, ABI-1179 and ABI-6250, are on track to enter clinical trials by the end of 2024.

On November 7, 2024, Assembly Biosciences, Inc., a biotechnology company, announced its financial results for the third quarter ending September 30, 2024. The company reported a cash position of $95.0 million, which is projected to fund operations into the first quarter of 2026. Revenue from collaborative research was $6.8 million, attributed to the collaboration with Gilead Sciences, Inc. Research and development expenses increased to $13.5 million due to more candidates in development, while general and administrative expenses remained stable at $4.3 million. The net loss for the quarter was $9.6 million, or $1.51 per share, an improvement from the $14.4 million loss in the same period of 2023. Assembly Biosciences also highlighted progress in its clinical pipeline, including positive Phase 1a interim data for ABI-5366, a candidate for recurrent genital herpes, and the initiation of Phase 1b trials. The company expects to release interim data for two other candidates, ABI-4334 and ABI-5366, by the end of 2024 and the first half of 2025, respectively. Additionally, two more candidates, ABI-1179 and ABI-6250, are on track to enter clinical trials by the end of 2024.